WellPoint Expands Access To Crestor Based On JUPITER Review

WellPoint is removing some obstacles to coverage for AstraZeneca's Crestor (rosuvastatin) in its commercial plans in recognition of the improved cardiovascular outcomes reported in the widely publicized JUPITER study. However, the drug will continue to be classified as a tier 3 non-preferred brand